#Israel #Tel Aviv #biotechnology #Greenberg Traurig #Entera Bio

Greenberg Traurig's Strategic Guidance for Entera Bio in Funding

In a recent development, the global law firm Greenberg Traurig, P.A. has effectively represented Entera Bio Ltd., an innovative biotechnology firm based in Israel, during a significant funding round. This particular private placement culminated in a remarkable total of $10 million, aimed at bolstering Entera’s endeavors in the realm of clinical biotechnology.

The funding round, which was dominated by BVF Partners L.P., a well-known private investment firm, finalized on April 2, 2026. Entera Bio successfully issued 7,827,789 units priced at $1.2775 each. Each unit comprises an ordinary share of Entera alongside a five-year warrant, allowing investors to purchase additional shares at an exercise price of $1.24 per share—an 11.7% premium based on Entera's most recent market close.

Funds Utilization and Future Plans
The proceeds from this transaction are earmarked for strategic utilization. Entera Bio has disclosed plans to channel the net proceeds alongside its existing financial resources into initiating its Phase 3 registrational trial of EB613, specifically targeting postmenopausal women diagnosed with osteoporosis. This initiative aims to deliver significant advancements in treatment options for this demographic that suffers from osteoporosis globally.

The leadership team at Greenberg Traurig assisting Entera was spearheaded by Drew M. Altman, who co-chairs the firm’s Miami Corporate Practice. He was supported by Corporate Shareholder Sami B. Ghneim and Law Clerk Elizabeth Ferrie. Their expertise played a crucial role in navigating the complexities of this funding process, demonstrating the firm’s robust capabilities in corporate law and its profound understanding of the biotech sector.

Envisioning Growth in Biotech
The essence of this funding not only reflects Entera Bio’s commitment to furthering biotechnology but also highlights the increasing investor confidence in innovative therapeutic approaches. The clinical-stage company is particularly focused on developing oral peptide and protein replacement therapies, a field that promises significant breakthroughs given the current limitations of existing therapies.

If all warrants from this offering are exercised, Entera Bio stands to gain an additional $14.5 million, potentially bringing the total funds available to around $24.5 million. This financial cushion will empower Entera Bio to pursue its research ambitions with vigor and possibly expedite the approval process of its product offerings pending regulatory scrutiny.

About Greenberg Traurig
Greenberg Traurig is globally recognized, with a legal workforce exceeding 3,100 lawyers across 51 locations worldwide. The firm’s broad array of practice areas and geographic footprint enables it to deliver exemplary legal support and strategic advice to clients across industries. Notably, Greenberg Traurig has been featured as a 2025 BTI “Best of the Best Recommended Law Firm,” acclaimed for its relationship management and trust established with clients. This accolade further solidifies its esteemed position in the legal sector, particularly in navigating complex transactions such as those witnessed in biotechnology.

In conclusion, the recent funding secured by Entera Bio represents not just a financial milestone, but also a strategic alliance with BVF Partners, guided effectively by Greenberg Traurig’s proficient legal team. As the firm continues to navigate the intricate timelines of biotech development, stakeholders will be watching closely to see how Entera Bio harnesses this influx of capital to transform their innovative visions into reality.